Inhibigens™ drive pro-tumor responses and may act through non-classical inhibitory mechanisms

• Published in: The Journal of immunology (1950) Vol. 206; no. 1_Supplement; pp. 29 - 29.06
• Main Authors: DeVault, Victoria L, Starobinets, Hanna, Arnold, Julie, Rinaldi, Stephanie, Odeh, Osaruese, Nguyen, Cindy, Flechtner, Jessica B, Lam, Hubert
• Format: Journal Article
• Language: English
• Published: 01.05.2021

Abstract The ATLAS™ platform screens a patient’s tumor mutanome with autologous T cells and antigen presenting cells to identify targets for cancer immunotherapy. Tumor mutations that lead to increased T cell responses are deemed stimulatory (neoantigens), while those rendering decreased responses a...